Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 2/20 | 0.36 |
| ▸ | RORC | P51449 | 4/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22101413 | 0.83 | MAPKAPK2 (0.37) | P2RX3SYKBRD4EGLN2CA12 | |
| SCHEMBL22101442 | 0.77 | P2RX3 (0.37) | P2RX3RORCSYKBRD4EGLN2 | |
| SCHEMBL22101865 | 0.76 | KCNQ3 (0.31) | PIK3CB | |
| SCHEMBL23608697 | 0.74 | SYK (0.39) | SYKEGLN2CA12CA1CA9 | |
| SCHEMBL22393588 | 0.74 | KCNQ3 (0.36) | — | |
| SCHEMBL22101522 | 0.72 | PIK3CB (0.37) | PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL22101697 | 0.70 | KCNQ3 (0.34) | PIK3CB | |
| SCHEMBL25839112 | 0.69 | CYP17A1 (0.38) | SYKEGLN2CA12CA1CA9 | |
| SCHEMBL30013712 | 0.69 | CYP17A1 (0.38) | SYKEGLN2CA12CA1CA9 | |
| SCHEMBL22101486 | 0.69 | KCNQ3 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230035184-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-02-02 | — | — | US | disclosed |
| US-11332465-B2 | Diarylthiohydantoin compound as androgen receptor antagonist | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-05-17 | — | — | US | disclosed |
| US-20200277290-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-09-03 | — | — | US | disclosed |
| EP-3666772-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230035184-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | AR, NR5A1, LHCGR | P2RX3 2446/4885RORC 194/4885SYK 4296/4885 |
| US-20200277290-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | AR, NR5A1, LHCGR | P2RX3 2446/4885RORC 194/4885SYK 4296/4885 |
| US-11332465-B2 | Diarylthiohydantoin compound as androgen receptor antagonist | AR, NR5A1, LHCGR | P2RX3 2446/4885RORC 194/4885SYK 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.